Canaccord Genuity set a $73.00 target price on Aerie Pharmaceuticals (NASDAQ:AERI) in a research note issued to investors on Monday morning. The brokerage currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. Cantor Fitzgerald set a $77.00 target price on Aerie Pharmaceuticals and gave the company a buy rating in a report on Monday. Needham & Company LLC reaffirmed a buy rating and issued a $76.00 target price (up previously from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Mizuho reaffirmed a buy rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. JMP Securities set a $68.00 target price on Aerie Pharmaceuticals and gave the company a buy rating in a report on Wednesday, October 11th. Finally, Cowen reaffirmed a buy rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. Aerie Pharmaceuticals currently has a consensus rating of Buy and an average target price of $72.00.

Shares of Aerie Pharmaceuticals (AERI) opened at $58.30 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24. Aerie Pharmaceuticals has a fifty-two week low of $35.50 and a fifty-two week high of $66.60.

Hedge funds have recently made changes to their positions in the business. Ameritas Investment Partners Inc. lifted its position in shares of Aerie Pharmaceuticals by 11.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after acquiring an additional 275 shares during the period. Quantbot Technologies LP lifted its position in shares of Aerie Pharmaceuticals by 792.5% in the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after acquiring an additional 2,647 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of Aerie Pharmaceuticals by 2,711.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the period. Amalgamated Bank bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter worth approximately $204,000. Finally, Great West Life Assurance Co. Can lifted its position in shares of Aerie Pharmaceuticals by 65.0% in the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after acquiring an additional 1,639 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Aerie Pharmaceuticals (AERI) Given a $73.00 Price Target at Canaccord Genuity” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/aerie-pharmaceuticals-aeri-given-a-73-00-price-target-at-canaccord-genuity/1772801.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.